Navigation Links
Developing Robust Potency Assays for Validation, New Webinar hosted by Xtalks
Date:1/30/2013

Toronto, Canada (PRWEB) January 30, 2013

Cell-based assays, or bioassays, are important for establishing safety, efficacy and stability profiles biopharmaceuticals. What’s more, these assays must be sufficiently robust to meet international regulatory and USP guidelines for system suitability. These tools are crucial for drug product lot release and stability testing to support licensing for commercialization.

Generally, assays are designed to demonstrate the relative potency of a product by comparing the biological response with a control preparation (such as USP, WHO, or an in-house reference standard). These assays are an essential component of the characterization/validation process and can be used to select candidates; establish comparability; test process intermediates, formulations and stability/degradation; and to support product changes.

In this webinar, our expert, Dr. Peter Wunderli, will review a case study for a biological drug product. Dr. Wunderli will go over topics including: the re-development of the bioassay method for potency and an improved process for extracting the drug product from a carrier so that the potency of the final drug product could be reproducibly measured.

For more information about this event or to register, visit: http://xtks.in/xto561-event

Xtalks is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com/ContactUs.ashx

Contact:
Karen Lim (416) 977-6555 ext 227
clientservices(at)xtalks(dot)com

Read the full story at http://www.prweb.com/releases/2013/1/prweb10375843.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Gated STED -- developing the next generation of super-resolution microscopes
2. Elsevier Foundation Awards 2011 Grants to Advance Women in Science and Support Libraries in Developing Countries
3. Frost & Sullivan Recognizes iCubate for Developing the New Gold Standard Instrument in the PCR Market
4. CNIO researchers describe a new target for developing anti-angiogenic and anti-tumoral therapies
5. SRI International Researchers Developing Bioadhesive Gel to Protect Women from HIV and HSV Infections
6. Carnegie Mellons Jeffrey Hollinger Leads Research Team Developing New Tools To Ease Pain of Combat Injuries
7. Elsevier Offers Entire Collection of Journals and Books to Innovators in Developing Countries Through the Access to Research for Development and Innovation (ARDI) Program
8. Phalanx Biotech Group Reports Robust Revenue Growth in 2011
9. endpoint Adopts New Technology To Boast Most Robust IVR Validation Objective Evidence and Decrease IVR Build Timelines
10. New nanotech fiber: Robust handling, shocking performance
11. Life Technologies Partners With DaAn Gene to Develop and Commercialize Molecular Diagnostic Assays in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... , Feb. 28, 2017 Sangamo ... genome editing, today reported its fourth quarter and ... "Early this year we rebranded our ... clinical development of genomic therapies using our industry ... gene regulation and cell therapy," said Sandy ...
(Date:2/27/2017)... ... February 27, 2017 , ... ... cold-pressed fruit and vegetable drink brand is now available on Amazon.com ... LLC to manufacture and distribute the Vegesentials line of juices throughout North ...
(Date:2/27/2017)... , Feb. 27, 2017 AcelRx Pharmaceuticals, ... on the development and commercialization of innovative therapies ... today the U.S. Food and Drug Administration (FDA) ... under section 505(b)(2) for DSUVIA™ (formerly ARX-04) (sufentanil ... patients with moderate-to-severe acute pain in a medically ...
(Date:2/27/2017)... -- Fluxion Biosciences announced today that Genetracer Biotech of ... as a Certified Service Provider for Fluxion,s IsoFlux CTC ... in Genetracer Biotech,s novel liquid biopsy workflows for detection ... plans to move to other cancers as additional assays ... to isolate, recover, and analyze CTCs (circulating tumor cells) ...
Breaking Biology Technology:
(Date:2/2/2017)... JACKSONVILLE, Fla. , Feb. 2, 2017 /PRNewswire/ ... ), a clinical-stage immuno-oncology company specializing in the ... vaccines for the treatment of cancer and metastatic ... multi-gram scale-up and GMP manufacturing of a second ... T-cell vaccine targeting folate receptor alpha. The manufactured ...
(Date:2/2/2017)... , Feb. 1, 2017  Central to its ... meaningful advances worldwide, The Japan Prize Foundation today ... who have pushed the envelope in their respective ... Communication. Three scientists are being recognized with the ... that not only contribute to the advancement of ...
(Date:1/31/2017)... Jan. 31, 2017  Spero Therapeutics, LLC, a ... the treatment of bacterial infections, today announced it ... candidates from Pro Bono Bio Ltd (PBB) to ... multi-drug resistant forms of Gram-negative bacteria.   The assets ... Ltd, a PBB group company. "The ...
Breaking Biology News(10 mins):